CMAJ • February 17, 2009; 180 (4). doi:10.1503/cmaj.081180.
© 2009 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Résumé
Right arrow Online Appendices
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cameron, C. G.
Right arrow Articles by Bennett, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cameron, C. G., MSc
Right arrow Articles by Bennett, H. A., BPharm PhD
Related Collections
Right arrowRelated Articles

Cost-effectiveness of insulin analogues for diabetes mellitus

Chris G. Cameron, MSc and Heather A. Bennett, BPharm PhD

Chris Cameron and Heather Bennett are with the Canadian Agency for Drugs and Technologies in Health, Ottawa, Ont.


Figure 117
View larger version (40K):
[in this window]
[in a new window]

  		Figure 1: Schematic representation of the Center for Outcomes Research Diabetes Model (adapted and simplified from the original schematic by Palmer and colleagues6,7). The cycle length is 1 day for mild to moderate hypoglycemia, 3 months for severe hypoglycemia and 1 month for ulcer submodels. All other submodels have a cycle length of 1 year.

 

View this table:
[in this window]
[in a new window]

  		Table 1.

 

View this table:
[in this window]
[in a new window]

  		Table 2.

 

View this table:
[in this window]
[in a new window]

  		Table 3.

 

View this table:
[in this window]
[in a new window]

  		Table 4.

 

Figure 217
View larger version (26K):
[in this window]
[in a new window]

  		Figure 2: Cost-effectiveness acceptability curves of insulin analogues for the treatment of type 1 and type 2 diabetes mellitus in adults, by treatment comparison. Costs are in 2007 Canadian dollars.